

IN THE CLAIMS:

✓  
Please amend claims 35-38 as follows:

35. (Amended) The method according to claim 34 wherein the inhibitors of TGFβ are selected from proteins, glycoproteins and proteoglycans.

71 36. (Amended) The method according to claim 35 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

37. (Amended) The method according to claim 35 wherein the glycoprotein inhibitors of TGFβ are selected from α<sub>2</sub>-macroglobulin, laminin and collagen.

Sub 43 38. (Amended) The method according to claim 35 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparin sulfate proteoglycans and biglycan.

REMARKS

35 U.S.C. § 101/112 Rejections

In the June 7, 2001 Office action, claims 35-38 were rejected under 35 U.S.C. § 101 as being the claimed recitation of a use, without setting forth any steps involved in the process, thereby resulting in an improper definition of a process. Further, claims 35-38 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite because the expression "The use" fails to clarify either a composition or method of use intended. In response to the Section 101